These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 16925744)
1. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? Finney SM; Andersson KE; Gillespie JI; Stewart LH BJU Int; 2006 Sep; 98(3):503-7. PubMed ID: 16925744 [TBL] [Abstract][Full Text] [Related]
2. Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure. Yokoyama O; Miwa Y; Oyama N; Aoki Y; Ito H; Akino H J Urol; 2007 Nov; 178(5):2208-12. PubMed ID: 17870108 [TBL] [Abstract][Full Text] [Related]
3. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. Kim Y; Yoshimura N; Masuda H; De Miguel F; Chancellor MB BJU Int; 2006 Feb; 97(2):400-3. PubMed ID: 16430654 [TBL] [Abstract][Full Text] [Related]
4. Voiding dysfunction after radical retropubic prostatectomy: more than external urethral sphincter deficiency. Porena M; Mearini E; Mearini L; Vianello A; Giannantoni A Eur Urol; 2007 Jul; 52(1):38-45. PubMed ID: 17403565 [TBL] [Abstract][Full Text] [Related]
5. Solifenacin succinate for the treatment of symptoms of overactive bladder. Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299 [TBL] [Abstract][Full Text] [Related]
7. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424 [TBL] [Abstract][Full Text] [Related]
8. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Kay GG; Granville LJ Clin Ther; 2005 Jan; 27(1):127-38; quiz 139-40. PubMed ID: 15763613 [TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298 [TBL] [Abstract][Full Text] [Related]
10. Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding. Groen J; Ruud Bosch JL; van Mastrigt R J Urol; 2006 Mar; 175(3 Pt 1):1005-9; discussion 1009. PubMed ID: 16469603 [TBL] [Abstract][Full Text] [Related]
11. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity. Bach P; Wormland RT; Möhring C; Goepel M Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067 [TBL] [Abstract][Full Text] [Related]
12. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. Kay GG; Abou-Donia MB; Messer WS; Murphy DG; Tsao JW; Ouslander JG J Am Geriatr Soc; 2005 Dec; 53(12):2195-201. PubMed ID: 16398909 [TBL] [Abstract][Full Text] [Related]
13. Objective measurement of bladder sensation: use of a new patient-activated device and response to neuromodulation. Craggs MD BJU Int; 2005 Sep; 96 Suppl 1():29-36. PubMed ID: 16086677 [TBL] [Abstract][Full Text] [Related]
14. Relationships between micturition urgency and involuntary voiding dynamics in men with urinary incontinence from idiopathic detrusor overactivity. Cucchi A; Quaglini S; Rovereto B J Urol; 2007 Aug; 178(2):563-7; discussion 567. PubMed ID: 17570436 [TBL] [Abstract][Full Text] [Related]
15. Case series data to encourage randomized trials of bladder retraining compared to antimuscarinic agents. Ghei M; Miller R; Malone-Lee J J Urol; 2006 Apr; 175(4):1411-5; discussion 1415-6. PubMed ID: 16516010 [TBL] [Abstract][Full Text] [Related]
16. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable? Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156 [TBL] [Abstract][Full Text] [Related]
17. The impact of tension-free vaginal tape on overactive bladder symptoms in women with stress urinary incontinence: significance of detrusor overactivity. Choe JH; Choo MS; Lee KS J Urol; 2008 Jan; 179(1):214-9. PubMed ID: 18001792 [TBL] [Abstract][Full Text] [Related]
18. Antimuscarinic mechanisms and the overactive detrusor: an update. Andersson KE Eur Urol; 2011 Mar; 59(3):377-86. PubMed ID: 21168951 [TBL] [Abstract][Full Text] [Related]
19. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. Grosse J; Kramer G; Jakse G BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Andersson KE; Chapple CR; Cardozo L; Cruz F; Hashim H; Michel MC; Tannenbaum C; Wein AJ Curr Opin Urol; 2009 Jul; 19(4):380-94. PubMed ID: 19448545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]